ClinicalTrials.gg
CompletedNCT04918784Updated Sep 28, 2023Results posted

Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers

An interventional study of Restrata® and Wound Dressing in Diabetic Foot Ulcer, sponsored by Acera Surgical, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.

Started
2021
with 1 other
No phase
8 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Diabetic Foot by Solventum, this one is one of 2 that started in 2021, is one of 8 with no phase, and was the 11th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetic Foot by Solventum as a file.
02

Study summary

The purpose of the following prospective, randomized, controlled clinical trial is to compare synthetic hybrid-scale fiber matrix (Restrata®, Acera Surgical, Inc.) with standard of care in treating diabetic foot ulcers in human subjects.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • Synthetic Hybrid-Scale Fiber Matrix
  • Diabetic Foot Ulcer
  • Epithelialization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is at least 18 years old
  2. Patient is willing and capable of complying with all protocol requirements
  3. Patient or legally authorized representative (LAR) is willing to provide written prior to or at the beginning of the run-in period
  4. Patient has Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per American Diabetes Association)
  5. Ulcer must be located at least in part on the foot or ankle
  6. Ulcer must be present for a minimum of 28 days prior to randomization and initial application of study product
  7. Wound size must be \< 30cm2 on the day of randomization and initial application of the study product, after initial debridement
  8. Patient has adequate circulation to the affected extremity, as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:

    1. Dorsum transcutaneous oxygen test (TcPO2) of study leg with results ≥40mmHg, OR
    2. Ankle-Brachial Index (ABI) of study leg with results of ≥ 0.7
    3. Toe-Brachial Index (TBI) of study extremity with results of > 50 mmHg

Exclusion criteria

Exclusion Criteria:

  1. Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint
  2. Patient is pregnant, breast feeding or planning to become pregnant
  3. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)
  4. Patient has a less than six months as assessed by the investigator
  5. Patient has received skin substitutes during the run-in period or within 14 days prior to beginning of run-in period
  6. Patient has an additional wound within 3 cm of the study wound
  7. A1c > 12% within 3 months prior to randomization in patients with a known history of diabetes
  8. Patient not in reasonable metabolic control in the judgment of the investigator
  9. Patient with a known history of poor compliance with medical treatments
  10. Patient currently undergoing cancer treatment
  11. Patient has been diagnosed with at least one of the following connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
  12. Patient is taking parenteral or any cytotoxic agents for 7 consecutive days during the run-in period or up to 30 days before the run-in period. Chronic oral steroid use is not excluded if dose is \< 10 mg per day for prednisone.
  13. Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgment of the investigator
  14. Osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence
  15. Patient unwilling to or unable to safely utilize appropriate offloading device to unweight wound
  16. Study ulcer spontaneously closes during the 2-week run in period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Treatment with Synthetic Hybrid-Scale Fiber Matrix

    Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.

    Device: Restrata®

  • Active comparator
    Treatment with Standard of Care

    Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.

    Device: Wound Dressing

Interventions

  • DeviceRestrata®

    Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.

    Also known as: Synthetic Hybrid-Scale Fiber Matrix

  • DeviceWound Dressing

    Alginate or Foam wound dressing is intended to manage wounds.

06

What researchers measure

Primary outcomes

  1. Number of Participants With 100% Re-epithelialization

    Primary outcome is number of participants with 100% epithelialization at 12 weeks of treatment as determined by investigator assessment of the ulcer and imaging.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Wound Area

    The difference in wound area from baseline to 100% re-epithelialization or week 12 will be summarized for each treatment group in each arm. Wound sizes were documented by the investigator at baseline to end of the treatment period for each participant.

    Time frame: 12 weeks

  2. Time to Wound Closure

    The number of weeks from initial application of study treatment until complete re-epithelialization is first identified.

    Time frame: Up to 12 Weeks

  3. Number of Treatment Applications

    The number of study treatment applications including the initial application until 12 weeks or until complete re-epithelialization, whichever occurs first.

    Time frame: 12 weeks

Other outcomes

  1. Quality of Life - SF-36

    The survey will be completed at the day of initial application and at either 12 weeks or at complete re-epithelialization

    Time frame: 12 weeks

  2. Cost Effectiveness / Economic Model

    Cost data from the patient's treatment will be analyzed based on diagnoses, procedure and supply codes to determine cost efficacy and outcomes with the treatment pathway and related technology utilized during the course of care.

    Time frame: 12 weeks

  3. Incidence of Adverse Events

    Time frame: 12 weeks

07

Results

Posted Sep 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
Started2521
Completed1918
Not completed63
Withdrew: Amputation - no longer eligible12
Withdrew: Death10
Withdrew: Patient non-compliance31
Withdrew: Adverse event10

Outcome measures

PrimaryNumber of Participants With 100% Re-epithelialization

Primary outcome is number of participants with 100% epithelialization at 12 weeks of treatment as determined by investigator assessment of the ulcer and imaging.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With 100% Re-epithelialization
ParticipantsTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
Number of Participants With 100% Re-epithelialization146
SecondaryChange in Wound Area

The difference in wound area from baseline to 100% re-epithelialization or week 12 will be summarized for each treatment group in each arm. Wound sizes were documented by the investigator at baseline to end of the treatment period for each participant.

Time frame:
12 weeks
Reported as:
Mean · Percentage of ulcer size decrease
Change in Wound Area
Percentage of ulcer size decreaseTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
Change in Wound Area89.3 ± 20.862.9 ± 56.0
SecondaryTime to Wound Closure

The number of weeks from initial application of study treatment until complete re-epithelialization is first identified.

Time frame:
Up to 12 Weeks
Reported as:
Mean · Number of weeks
Time to Wound Closure
Number of weeksTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
Time to Wound Closure6.57 ± 3.07.0 ± 2.9
SecondaryNumber of Treatment Applications

The number of study treatment applications including the initial application until 12 weeks or until complete re-epithelialization, whichever occurs first.

Time frame:
12 weeks
Reported as:
Mean · Average number of treatment applications
Number of Treatment Applications
Average number of treatment applicationsTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
Number of Treatment Applications6.8 ± 3.57.7 ± 3.5
Other pre-specifiedQuality of Life - SF-36

The survey will be completed at the day of initial application and at either 12 weeks or at complete re-epithelialization

Time frame:
12 weeks

Results for this outcome have not been posted.

Other pre-specifiedCost Effectiveness / Economic Model

Cost data from the patient's treatment will be analyzed based on diagnoses, procedure and supply codes to determine cost efficacy and outcomes with the treatment pathway and related technology utilized during the course of care.

Time frame:
12 weeks

Results for this outcome have not been posted.

Other pre-specifiedIncidence of Adverse Events
Time frame:
12 weeks

Results for this outcome have not been posted.

Adverse events

Collected over For each individual patient, data was collected over the 12 week treatment period or until complete re-epithelialization and 2 week follow up visit, up to a maximum of 14 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment With Synthetic Hybrid-Scale Fiber Matrix1/25 (4%)2/25 (8%)6/25 (24%)
Treatment With Standard of Care0/21 (0%)2/21 (9.5%)2/21 (9.5%)
Most frequent serious events
Most frequent serious events
EventTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
AmputationSkin and subcutaneous tissue disorders1/252/21
Cerebral vascular accidentCardiac disorders1/250/21
Most frequent other events
Most frequent other events
EventTreatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of Care
InfectionSkin and subcutaneous tissue disorders6/252/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of CareTotal
<=18 years000
Between 18 and 65 years101020
>=65 years151126
Sex: Female, Male
Sex: Female, Male(Participants)Treatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of CareTotal
Female8412
Male171734
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of CareTotal
Hispanic or Latino628
Not Hispanic or Latino191938
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment With Synthetic Hybrid-Scale Fiber MatrixTreatment With Standard of CareTotal
American Indian or Alaska Native000
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American123
White211738
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Midwest Foot and Ankle Clinics
    Hoffman Estates, Illinois 60169, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2022, 14 months.

Results were first posted in Sep 2023, 1 year 1 month after primary completion.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 14 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
Jun 9, 2021
StartActual
May 5, 2021
Primary completionActual
Jul 31, 2022
CompletionActual
Dec 1, 2022
Results first posted
Sep 21, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04918784
Responsible party
Sponsor
First posted
Jun 9, 2021
Start date
May 5, 2021
Primary completion
Jul 31, 2022
Completion
Dec 1, 2022
Results posted
Sep 21, 2023
Last update
Sep 28, 2023

Study contacts

Khalid Husain, DPM
principal investigator · Midwest Foot & Ankle Clinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion